| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2016 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 32 | Q2 2024 | 68.0% |
| DENALI THERAPEUTICS INC | 26 | Q1 2024 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 23 | Q2 2024 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| Foghorn Therapeutics Inc | 15 | Q2 2024 | 8.6% |
| Sana Biotechnology Inc | 14 | Q2 2024 | 18.4% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 13F-HR | 2024-08-14 |
| 4 | 2024-05-24 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.